Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 706,700 shares, a decline of 27.2% from the March 15th total of 971,000 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average trading volume of 21,680,000 shares, the days-to-cover ratio is presently 0.0 days.
Sunshine Biopharma Price Performance
Shares of SBFM traded down $0.01 on Friday, hitting $0.08. The company’s stock had a trading volume of 16,534,116 shares, compared to its average volume of 24,975,060. The company has a market capitalization of $7.97 million, a PE ratio of -0.42 and a beta of 1.17. Sunshine Biopharma has a fifty-two week low of $0.04 and a fifty-two week high of $1.40. The company has a 50 day moving average price of $0.09 and a 200 day moving average price of $0.21.
Sunshine Biopharma’s stock is going to reverse split on Wednesday, April 17th. The 1-100 reverse split was announced on Wednesday, April 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, April 17th.
Institutional Trading of Sunshine Biopharma
Sunshine Biopharma Company Profile
Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.
See Also
- Five stocks we like better than Sunshine Biopharma
- What is a Death Cross in Stocks?
- 5 Trends You Need to Know This Quarter
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 4/8 – 4/12
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- You Can Follow BlackRock’s Market View for Your Money
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.